Trial Profile
A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 20 Oct 2020 Status changed from active, no longer recruiting to completed.
- 12 May 2020 Planned End Date changed from 1 Sep 2020 to 28 Jul 2020.
- 12 May 2020 Planned primary completion date changed from 1 Sep 2020 to 28 Jul 2020.